Adicet Bio, Inc. (0HX7.L)

USD 0.92

(-3.81%)

Total Debt Summary of Adicet Bio, Inc.

  • Adicet Bio, Inc.'s latest annual total debt in 2023 was 17.7 Million USD , down -0.47% from previous year.
  • Adicet Bio, Inc.'s latest quarterly total debt in 2024 Q1 was 20.03 Million USD , down -4.24% from previous quarter.
  • Adicet Bio, Inc. reported annual total debt of 21.02 Million USD in 2022, up 0.38% from previous year.
  • Adicet Bio, Inc. reported annual total debt of 20.94 Million USD in 2021, down -3.21% from previous year.
  • Adicet Bio, Inc. reported quarterly total debt of 19.13 Million USD for 2024 Q2, down -4.51% from previous quarter.
  • Adicet Bio, Inc. reported quarterly total debt of 21.79 Million USD for 2023 Q3, down -3.73% from previous quarter.

Annual Total Debt Chart of Adicet Bio, Inc. (2023 - 2017)

Historical Annual Total Debt of Adicet Bio, Inc. (2023 - 2017)

Year Total Debt Total Debt Growth
2023 17.7 Million USD -0.47%
2022 21.02 Million USD 0.38%
2021 20.94 Million USD -3.21%
2020 21.63 Million USD -81.03%
2019 114.08 Million USD 3564.73%
2018 3.11 Million USD 0.0%
2017 - USD 0.0%

Peer Total Debt Comparison of Adicet Bio, Inc.

Name Total Debt Total Debt Difference
Editas Medicine, Inc. 36.53 Million USD 51.546%
Dynavax Technologies Corporation 256.91 Million USD 93.109%
Supernus Pharmaceuticals, Inc. 41.52 Million USD 57.37%
Perrigo Company plc 4.07 Billion USD 99.565%
Illumina, Inc. 2.26 Billion USD 99.217%
Thermo Fisher Scientific Inc. 34.91 Billion USD 99.949%
Iovance Biotherapeutics, Inc. 1 Million USD -1670.3%
Walgreens Boots Alliance, Inc. 9.55 Billion USD 99.815%
IQVIA Holdings Inc. 14.23 Billion USD 99.876%
Heron Therapeutics, Inc. 173.75 Million USD 89.811%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 99.345%
Unity Biotechnology, Inc. 26.99 Million USD 34.409%
Waters Corporation 2.35 Billion USD 99.248%
Biogen Inc. 7.33 Billion USD 99.759%
Sangamo Therapeutics, Inc. 38.1 Million USD 53.54%
Evolus, Inc. 126.54 Million USD 86.011%
Cara Therapeutics, Inc. 43.16 Million USD 58.99%
bluebird bio, Inc. 330.32 Million USD 94.641%
Esperion Therapeutics, Inc. 540.94 Million USD 96.727%
FibroGen, Inc. 170.45 Million USD 89.614%
Agilent Technologies, Inc. 2.73 Billion USD 99.353%
Corbus Pharmaceuticals Holdings, Inc. 20.88 Million USD 15.233%
Homology Medicines, Inc. 44.05 Million USD 59.815%
Geron Corporation 85.89 Million USD 79.391%
Alnylam Pharmaceuticals, Inc. 2.39 Billion USD 99.262%
Amicus Therapeutics, Inc. 445.05 Million USD 96.022%
Myriad Genetics, Inc. 145 Million USD 87.791%
Viking Therapeutics, Inc. 1.26 Million USD -1305.0%
Intellia Therapeutics, Inc. 115.34 Million USD 84.652%
Zoetis Inc. 6.8 Billion USD 99.74%
Abeona Therapeutics Inc. 4.4 Million USD -302.158%
Mettler-Toledo International Inc. 2.16 Billion USD 99.183%
BioMarin Pharmaceutical Inc. 1.13 Billion USD 98.439%
Vertex Pharmaceuticals Incorporated 808.4 Million USD 97.81%
Kala Pharmaceuticals, Inc. 36.32 Million USD 51.262%
Ionis Pharmaceuticals, Inc. 1.45 Billion USD 98.782%
Atara Biotherapeutics, Inc. 57.87 Million USD 69.41%
Verastem, Inc. 41.55 Million USD 57.401%
Nektar Therapeutics 230.4 Million USD 92.316%
Axsome Therapeutics, Inc. 186.37 Million USD 90.501%
Aclaris Therapeutics, Inc. 3.07 Million USD -475.895%
Sarepta Therapeutics, Inc. 1.39 Billion USD 98.733%
OPKO Health, Inc. 326.56 Million USD 94.579%
Exelixis, Inc. 189.94 Million USD 90.68%
Neurocrine Biosciences, Inc. 428.4 Million USD 95.868%
Corcept Therapeutics Incorporated 151 Thousand USD -11623.841%
Anavex Life Sciences Corp. - USD -Infinity%
uniQure N.V. 138.4 Million USD 87.21%
Imunon, Inc. 1.13 Million USD -1453.858%
Blueprint Medicines Corporation 774.12 Million USD 97.713%
Insmed Incorporated 1.2 Billion USD 98.53%
Halozyme Therapeutics, Inc. 1.49 Billion USD 98.819%
Agios Pharmaceuticals, Inc. 56.98 Million USD 68.936%
TG Therapeutics, Inc. 110.79 Million USD 84.022%
Incyte Corporation 38.28 Million USD 53.762%
Emergent BioSolutions Inc. 877.5 Million USD 97.983%